Tempest Therapeutics (TPST) said Thursday that the mid-stage clinical trial of TPST-1495 for the treatment of familial adenomatous polyposis has received a "study may proceed" letter from the US Food and Drug Administration.
The clinical-stage company said the Cancer Prevention Clinical Trials Network will run the mid-stage study, which will start this year and funded by the National Cancer Institute Division of Cancer Prevention.
Shares of the company were up more than 1% in recent premarket activity on Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.